rhodamine 123 has been researched along with solutol hs 15 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clodfelter, K; Coon, JS; Knudson, W; Lu, B; Weinstein, RS | 1 |
| Balasubramanian, M; Buckingham, LE; Clodfelter, KE; Coon, JS; Emanuele, RM | 1 |
| Anderson, KM; Buckingham, L; Coon, JS; Dudeja, PK; Harris, JS | 1 |
| Chen, L; Deng, Y; Gao, Y; Ji, X; Li, Y; Zhang, Z | 1 |
4 other study(ies) available for rhodamine 123 and solutol hs 15
| Article | Year |
|---|---|
Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance.
Topics: Carcinoma, Squamous Cell; Cell Membrane Permeability; Chromatography, Gel; Colchicine; Doxorubicin; Drug Resistance; Humans; Polyethylene Glycols; Rhodamine 123; Rhodamines; Stearic Acids; Tumor Cells, Cultured; Verapamil; Vinblastine | 1991 |
Comparison of solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents.
Topics: Antineoplastic Agents; Cell Line; Drug Resistance, Multiple; Glycerol; Humans; Polyethylene Glycols; Rhodamine 123; Rhodamines; Stearic Acids; Surface-Active Agents | 1995 |
Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity.
Topics: Cell Line; Diphenylhexatriene; Drug Resistance, Multiple; Flow Cytometry; Fluorescence Polarization; Fluorescent Dyes; Glucosides; Humans; Membrane Fluidity; Membrane Lipids; Phenotype; Polyethylene Glycols; Rhodamine 123; Rhodamines; Stearic Acids; Surface-Active Agents | 1995 |
Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Compounding; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glycerol; Humans; Lipids; Liposomes; Lung Neoplasms; Nanotechnology; Paclitaxel; Particle Size; Poloxamer; Polyethylene Glycols; Rhodamine 123; Solubility; Stearic Acids; Surface-Active Agents; Technology, Pharmaceutical; Time Factors | 2012 |